Is There a Genetic Test for Lewy Body Dementia?

No single genetic test can diagnose or reliably predict Lewy body dementia (LBD). The condition’s genetic architecture involves a mix of common gene variants with individually small effects and rare mutations that carry larger ones, so no one gene works like a simple on-off switch. Researchers have identified several genes that shape risk, and experimental scoring tools show promise in research settings, but the gap between a laboratory finding and a test your doctor can order remains wide.

Why No Single-Gene Test Exists

LBD’s genetic landscape is fundamentally different from conditions where one gene tells the whole story. The genetic architecture involves both common variants with small risk effects and rare variants with large effects, producing a spectrum of susceptibility rather than a binary outcome.¹ Unlike Huntington’s disease, where a single gene expansion gives a near-certain prediction, LBD arises from contributions spread across many genes, each adding a small push toward or away from disease. A few rare mutations carry larger effects, but even those don’t guarantee someone will develop LBD. The result is that no laboratory has been able to package LBD genetics into a yes-or-no diagnostic.

This doesn’t mean genetics are irrelevant. Several specific genes consistently appear in studies of people with LBD, and understanding them helps researchers gauge risk, classify disease subtypes, and identify future treatment targets.

Three Genes That Shape LBD Risk

GBA

The GBA gene provides instructions for making an enzyme called glucocerebrosidase, which helps break down certain fats inside cells. Mutations in GBA are among the strongest known genetic risk factors for Lewy body diseases.² In one study of white participants, pathogenic GBA mutations appeared in about 8% of people with pure dementia with Lewy bodies, compared to less than 1% of healthy controls, roughly a sevenfold increase in odds.³ The same study found that GBA mutations were also more common in people who had both LBD and Alzheimer’s pathology, though the risk increase was smaller. Carrying a GBA mutation doesn’t mean you’ll develop LBD. Many carriers never do. But the gene clearly loads the dice.

APOE ε4

APOE ε4 is best known as the leading genetic risk factor for Alzheimer’s disease, and its connection to LBD initially seemed like it might simply reflect overlapping Alzheimer’s pathology in the brain. Research has challenged that assumption. One study found that APOE ε4 was independently linked to more severe Lewy body pathology, even in brains without much Alzheimer’s co-pathology, with a roughly threefold increase in risk of diffuse Lewy body disease in that group.⁴ Earlier work found a similar threefold increase in ε4 frequency among people with LBD compared to age-matched controls, a magnitude matching what’s seen in Alzheimer’s itself.⁵

The relationship between APOE ε4 and LBD seems to be more about spreading the disease than starting it. Evidence suggests ε4 acts as a modifier, favoring the spread of Lewy body pathology through the brain rather than directly initiating it.⁴

SNCA

The SNCA gene encodes alpha-synuclein, the protein that clumps together to form the Lewy bodies defining the disease. Mutations in SNCA were first linked to LBD when specific point mutations and gene duplications turned up in families where parkinsonism and dementia ran together.⁶ These mutations are extremely rare but can cause devastating early-onset disease. In one family, a person who carried two extra copies of SNCA (homozygous duplication) developed symptoms earlier and died sooner than relatives who carried just one extra copy.⁷

SNCA mutations show striking variability even within the same family. Some carriers develop classic Parkinson’s disease, others develop LBD, and still others develop a different neurodegenerative condition entirely. Not all SNCA duplications are fully penetrant, meaning some carriers may never develop disease at all.⁶ That kind of unpredictability is one more reason a simple genetic test can’t deliver a straightforward LBD diagnosis.

Different Genetic Profiles May Mean Different Disease Subtypes

One of the more revealing findings in recent years is that LBD isn’t genetically uniform. When researchers separated patients by whether or not they carried APOE ε4, GBA emerged as a strong risk factor for LBD in people without ε4, with roughly a threefold increase in risk, but the association weakened considerably in ε4 carriers. Meanwhile, APOE ε4 was strongly linked to LBD cases that also had significant Alzheimer’s pathology but was not associated with pure LBD lacking Alzheimer’s features.⁸

This suggests there may be at least two genetically distinct roads to LBD. One is driven more by GBA and problems with how cells recycle their contents. The other is driven more by APOE ε4 and tends to come packaged with Alzheimer’s co-pathology. The clinical implications are still being worked out, but the pattern matters because treatments targeting one pathway may not help patients whose disease was driven by the other. For the question of genetic testing, it means a single panel checking one gene would miss the other route entirely.

Polygenic Risk Scores as Research Tools

Rather than testing a single gene, polygenic risk scores combine the small effects of thousands of gene variants into one number that estimates overall genetic susceptibility. Several research groups have explored these scores for LBD, though none are used in routine clinical practice yet.

One study found that combining a polygenic Alzheimer’s risk score, an APOE-based risk score, and a blood biomarker called p-tau181 could distinguish people with LBD from those with Alzheimer’s with about 75% accuracy and could detect amyloid-beta positivity within the LBD group at about 82%.⁹ A separate study focused on genes involved in lysosomal function found that a pathway-specific polygenic score was more consistently associated with Lewy pathology than a general Parkinson’s disease risk score, especially in people without significant Alzheimer’s co-pathology.¹⁰

Work in a Chinese population generated a whole-genome polygenic risk score that distinguished LBD patients from controls with about 70% accuracy. Patients in the highest quarter of genetic risk had an earlier average age of onset, roughly 67 compared to about 70 in the lowest quarter, and higher cumulative incidence rates at any given age.¹¹

These accuracy levels aren’t high enough for a standalone diagnostic test. Roughly 70-75% accuracy means too many false positives and missed cases to rely on genetic scores alone. The most likely near-term use is as one input alongside brain imaging, fluid biomarkers, and clinical evaluation, rather than as a replacement for any of them.

How LBD Shares Genetic Roots with Alzheimer’s and Parkinson’s

LBD sits in an awkward genetic neighborhood between Alzheimer’s disease and Parkinson’s disease, sharing substantial genetic architecture with both. Large-scale analyses have found strong positive genetic correlations between LBD and Alzheimer’s, and between LBD and Parkinson’s, while the correlation between Alzheimer’s and Parkinson’s themselves is weaker.¹² Specific genetic loci, including regions near the TMEM175 and HLA genes, appear to be shared across three or more neurodegenerative conditions.¹³

This overlap helps explain why LBD so often co-occurs with Alzheimer’s pathology and why many LBD patients initially receive an Alzheimer’s or Parkinson’s diagnosis instead. It also means that genetic risk information has to be interpreted carefully. A high-risk APOE ε4 result, for instance, doesn’t tell you whether the road ahead leads to Alzheimer’s, LBD, or some combination. For a person considering genetic testing, the takeaway is that a positive result for a gene associated with neurodegeneration generally raises a flag for several possible conditions, not one specific diagnosis.

Non-Genetic Diagnostic Approaches

While genetic testing for LBD remains in the research phase, other diagnostic technologies have made faster progress. The alpha-synuclein seed amplification assay (SAA) detects misfolded alpha-synuclein protein in body fluids or tissue samples, and it’s drawn considerable excitement. In a study comparing LBD and Alzheimer’s patients, SAA achieved about 87% diagnostic accuracy when performed on cerebrospinal fluid and about 85% when performed on skin biopsies.¹⁴

SAA is notable because it detects the actual pathological protein rather than predicting risk from genetic variants. Rather than asking “do you carry genes that raise your risk?” it asks “is the disease process already under way?” It isn’t yet widely available outside research settings, but it represents a fundamentally different and complementary approach. A future diagnostic workup might combine genetic risk information, SAA results, brain imaging, and clinical assessment to reach a more confident diagnosis earlier in the disease course than any single tool currently allows.

What Direct-to-Consumer Genetic Tests Can Tell You

Consumer genetic testing services report on certain variants, including APOE status, which can influence both Alzheimer’s and LBD risk. But these reports come with serious limitations. They typically test only a handful of well-known variants, missing rare mutations in genes like GBA or SNCA that carry larger effects. The risk estimates they provide are population-level averages, not individualized predictions tailored to your medical history, lifestyle, or other genetic background.

Testing for neurodegenerative conditions raises particular ethical and communication challenges, including questions about informed consent, the psychological impact of learning about risk for a condition with no cure, and the potential for genetic discrimination.¹⁵ These concerns are amplified when the test results are ambiguous, which, given the current state of LBD genetics, they almost always are. If you’re considering consumer testing and have a family history of LBD or related conditions, speaking with a genetic counselor beforehand can help you understand what the results will and won’t mean.

The Emotional Weight of Testing

For families where LBD or related conditions have appeared across generations, the decision about genetic testing is deeply personal. Research into how families navigate these choices finds that the decision is guided more by values than by medical calculation. People who chose testing wanted to provide information about heredity to their children, reduce nagging uncertainty, or gain a sense of agency. People who declined worried about the psychological toll on family members or felt the timing in their lives wasn’t right.¹⁶

Studies following people through the testing process found that those who received negative results felt relieved their children weren’t at genetic risk, though some remained uncertain about the cause of their own disease. Those who received positive results experienced distress about the implications for their children but also valued having clarity. Decision regret was low regardless of outcome, suggesting most people felt they’d made the right call. Still, family members connected to positive cases reported challenges in finding emotional support, underscoring the need for counseling that extends beyond the person tested.¹⁷

The Diversity Gap in LBD Genetics Research

Almost all of the large genetic studies of LBD have been conducted in people of European ancestry. Researchers have explicitly acknowledged this as a limitation, calling for the inclusion of diverse populations to build a complete picture of the genetic factors driving the disease.¹⁸ Without that data, it’s impossible to know whether the risk genes and polygenic scores developed so far apply equally across ethnic groups, or whether some populations carry distinct risk profiles that current research hasn’t captured.

This isn’t a hypothetical concern. In Alzheimer’s genetics, APOE ε4 carries different risk levels in different ancestral populations. Similar variation likely exists for LBD but hasn’t been adequately measured. The polygenic risk study conducted in a Chinese population is one of the few exceptions, and even it was relatively modest in size.¹¹ Until research broadens its participant base, genetic risk information for LBD should be understood as most reliable for people of European descent and less certain for everyone else.

Gene Therapy on a Distant Horizon

One reason the genetic underpinnings of LBD matter even without a clinical genetic test is that they point toward future treatment targets. Gene therapy, which aims to correct or compensate for faulty genes, is being explored across several types of dementia, including LBD. For LBD specifically, researchers are interested in whether boosting glucocerebrosidase activity in GBA mutation carriers or reducing alpha-synuclein production in SNCA-related cases could slow or prevent disease. These approaches are in early stages, and clinical trials will be needed before any conclusions about safety or effectiveness can be drawn. But the fact that some LBD cases trace to identifiable genetic pathways makes them, in principle, candidates for gene-based intervention in a way that cases driven by dozens of tiny risk variants may not be. The identification of genetically distinct LBD subtypes could eventually allow clinicians to match patients to therapies targeting their specific molecular pathway, a precision-medicine approach that depends on the kind of genetic characterization researchers are building now.